Journal
SEMINARS IN THROMBOSIS AND HEMOSTASIS
Volume 34, Issue 4, Pages 356-360Publisher
THIEME MEDICAL PUBL INC
DOI: 10.1055/s-0028-1085478
Keywords
antiphospholipid antibodies; immunoassays; automation; antiphospholipid syndrome
Categories
Ask authors/readers for more resources
The pathogenic role of antiphospholipid antibodies (aPL) has been widely established over past years in several experimental models and clinical studies. Accordingly, the detection of aPL by immunoassays (anticardiolipin antibodies; anti-beta 2 glycoprotein I antibodies) has become a routine practice in the clinical workup of patients with systemic autoimmune diseases. aPL are mostly assayed using commercial ELISA kits, whose performance has not been found to be sufficiently concordant among the different manufacturers. In the past years, collaborative groups have spent considerable effort to reach some form of standardization but this process is still ongoing. Such lack of standardization has recently become even more crucial, as manufacturers have had to face an increasing demand for fully automated tests for aPL, like those test systems that have been developed for other autoantibodies (e.g., antinuclear antibodies, anti-ENA antibodies). We therefore report our recent experience with two newly developed automated methods for anticardiolipin antibodies testing. In particular, we discuss the results obtained using routine samples, as we believe that these better reflect the real-life situation in which those automated methods will operate. We also mention other emerging technologies in the field of aPL detection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available